By Danny Sullivan – Longevity.Technoloy –
Longevity biotech Clock.bio has secured $5.3 million in seed funding to support its mission to extend human healthspan via the self-rejuvenation mechanisms present in stem cells. The company also revealed it has completed its initial objective of decoding the biology of rejuvenation across the entire human genome, leading to the discovery of over 100 genes that form what it is calling an “Atlas of Rejuvenation Factors.”
Based at the Milner Therapeutics Institute at the University of Cambridge, Clock.bio has been working with human induced pluripotent stem cells (iPSCs), which have a unique capacity to reverse aging. In contrast to somatic cells, which age irreversibly, stem cells can naturally rejuvenate.
